Bernstein Liebhard LLP Announces Investigation Of Acquisition Of ISTA Pharmaceuticals, Inc. By Bausch + Lomb
NEW YORK, March 27, 2012 /PRNewswire/ -- Bernstein Liebhard LLP is investigating whether the Board of Directors of ISTA Pharmaceuticals, Inc. ("ISTA" or the "Company") (NASDAQ: ISTA) breached its fiduciary duty to its shareholders in agreeing to sell ISTA to Bausch + Lomb.
Under the terms of the agreement, ISTA shareholders will receive $9.10 in cash for each share they own. The investigation is focused on the potential unfairness of the price to ISTA shareholders and the process by which the ISTA Board of Directors considered and approved the transaction.
If you are interested in discussing your rights as an ISTA stockholder, with no obligation or cost to you, please contact
U. Seth Ottensoser at:
(877) 779-1414or Ottensoser@bernlieb.com.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts